Glenmark Life Sciences Ltd
GLSGlenmark Life Sciences Ltd
GLS
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 30.25 | 5.49 | 2.15% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 50.09 | 6.40 | 0.53% |
Forecast & Ratings
Detailed Forecast from 6 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Glenmark Life Sciences Ltd is a manufacturer of pharmaceutical preparation. The Company was founded in June 2011 and is located in Solapur, India.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.25 | 886.86 | 1,549.30 | 1,885.98 | 2,137.91 | 2,190.18 | 2,295.25 | 2,223.75 | ||||||||
Raw Materials | 0.04 | 633.56 | 668.66 | 948.17 | 977.96 | 1,068.56 | 1,025.21 | 1,597.05 | ||||||||
| Power & Fuel Cost | 0.00 | 57.81 | 76.75 | 74.19 | 100.92 | 115.60 | 112.46 | |||||||||
| Employee Cost | 0.15 | 106.28 | 142.28 | 149.13 | 168.72 | 180.18 | 258.16 | |||||||||
| Selling & Administrative Expenses | 0.00 | 44.20 | 42.05 | 48.50 | 48.64 | 65.47 | 64.12 | |||||||||
| Operating & Other expenses | 0.08 | -203.15 | 135.61 | 74.11 | 210.91 | 89.11 | 149.02 | |||||||||
EBITDA | -0.02 | 248.16 | 483.95 | 591.88 | 630.76 | 671.26 | 686.28 | 626.70 | ||||||||
| Depreciation/Amortization | 0.00 | 19.26 | 29.37 | 33.39 | 37.88 | 42.09 | 53.45 | 57.19 | ||||||||
| PBIT | -0.02 | 228.90 | 454.58 | 558.49 | 592.88 | 629.17 | 632.83 | 569.51 | ||||||||
| Interest & Other Items | 0.00 | 0.61 | 33.52 | 87.55 | 27.96 | 0.55 | 1.55 | 1.44 | ||||||||
| PBT | -0.02 | 228.29 | 421.06 | 470.94 | 564.92 | 628.62 | 631.28 | 568.07 | ||||||||
| Taxes & Other Items | 0.42 | 32.71 | 107.97 | 119.37 | 146.20 | 161.65 | 160.40 | 144.56 | ||||||||
| Net Income | -0.44 | 195.58 | 313.09 | 351.57 | 418.72 | 466.97 | 470.88 | 423.51 | ||||||||
| EPS | -8.00 | 36.10 | 29.04 | 32.61 | 36.36 | 38.11 | 38.43 | 34.56 | ||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 21.00 | 42.00 | 22.50 | 22.50 | ||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.58 | 1.10 | 0.59 | 0.65 |
Company Updates
Investor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Glenmark Life Sciences Ltd | 27.21 | 5.49 | 2.15% |
| Sun Pharmaceutical Industries Ltd | 44.98 | 6.42 | 0.75% |
| Cipla Ltd | 29.13 | 4.48 | 0.87% |
| Torrent Pharmaceuticals Ltd | 64.71 | 15.63 | 0.88% |
Price Comparison
Compare GLS with any stock or ETFShareholdings
Promoter Holdings Trend
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 7.85%
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 1.39%
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 3.04%
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 1.80%
Top 5 Mutual Funds holding Glenmark Life Sciences Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Quant Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8979% | Percentage of the fund’s portfolio invested in the stock 1.53% | Change in the portfolio weight of the stock over the last 3 months 1.53% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 45/46 (+1) |
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Plan Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.4208% | Percentage of the fund’s portfolio invested in the stock 1.08% | Change in the portfolio weight of the stock over the last 3 months -0.50% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 30/51 (-10) |
Quant Business Cycle Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.4105% | Percentage of the fund’s portfolio invested in the stock 3.40% | Change in the portfolio weight of the stock over the last 3 months 3.40% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 12/43 (+25) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateOct 17, 2023
Dividend/Share
₹22.50
Ex DateEx Date
Oct 17, 2023
Cash Dividend
Ex DateEx DateMar 24, 2023
Dividend/Share
₹21.00
Ex DateEx Date
Mar 24, 2023
Cash Dividend
Ex DateEx DateSep 15, 2022
Dividend/Share
₹10.50
Ex DateEx Date
Sep 15, 2022
Cash Dividend
Ex DateEx DateNov 22, 2021
Dividend/Share
₹10.50
Ex DateEx Date
Nov 22, 2021
Net profit of Glenmark Life Sciences declined 19.72% to Rs 95.32 crore in the quarter ended September 2024 as against Rs 118.74 crore during the previous quarter ended September 2023. Sales declined 14.86% to Rs 506.88 crore in the quarter ended September 2024 as against Rs 595.36 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales506.88595.36 -15 OPM %26.5128.07 - PBDT142.55172.06 -17 PBT127.46158.93 -20 NP95.32118.74 -20 Powered by Capital Market - Live
Glenmark Life Sciences will hold a meeting of the Board of Directors of the Company on 24 October 2024.Powered by Capital Market - Live
Glenmark Life Sciences announced that the Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live
HUL, Lux Industries shares gain despite market crash
Glenmark Life Sciences Ltd leads gainers in ‘A’ group
Tamilnad Mercantile Bank Ltd, Marico Ltd, Rossari Biotech Ltd and Nestle India Ltd are among the other gainers in the BSE's 'A' group today, 05 August 2024.Glenmark Life Sciences Ltd soared 6.76% to Rs 939.3 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 23295 shares were traded on the counter so far as against the average daily volumes of 23721 shares in the past one month. Tamilnad Mercantile Bank Ltd spiked 3.68% to Rs 468.7. The stock was the second biggest gainer in 'A' group. On the BSE, 1.84 lakh shares were traded on the counter so far as against the average daily volumes of 11409 shares in the past one month. Marico Ltd surged 1.94% to Rs 674.8. The stock was the third biggest gainer in 'A' group. On the BSE, 96840 shares were traded on the counter so far as against the average daily volumes of 1.4 lakh shares in the past one month. Rossari Biotech Ltd gained 1.07% to Rs 918.7. The stock was the fourth biggest gainer in 'A' group. On the BSE, 89730 shares were traded on the counter so far as against the average daily volumes of 19439 shares in the past one month. Nestle India Ltd advanced 0.68% to Rs 2511.3. The stock was the fifth biggest gainer in 'A' group. On the BSE, 16742 shares were traded on the counter so far as against the average daily volumes of 51971 shares in the past one month. Powered by Capital Market - Live
Stock that will see action today: July 29, 2024
Glenmark Life drops after Q1 PAT slides 18% YoY to Rs 111 cr
Glenmark Life Sciences standalone net profit declines 17.70% in the June 2024 quarter
Net profit of Glenmark Life Sciences declined 17.70% to Rs 111.48 crore in the quarter ended June 2024 as against Rs 135.45 crore during the previous quarter ended June 2023. Sales rose 1.76% to Rs 588.62 crore in the quarter ended June 2024 as against Rs 578.45 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales588.62578.45 2 OPM %27.1033.39 - PBDT164.63194.62 -15 PBT150.24182.01 -17 NP111.48135.45 -18 Powered by Capital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 20.95%, vs industry avg of 9.03%
Increasing Market Share
Over the last 5 years, market share increased from 0.4% to 0.61%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 19.21%, vs industry avg of 15.28%